Evaluation of COVID-19 protease and HIV inhibitors interactions

Tran, Linh; Tam, Dao Ngoc Hien; Elhadad, Heba; Hien, Nguyen Minh; Huy, Nguyen Tien

doi:10.2478/acph-2022-0010

Abstract

The epidemic of the novel coronavirus disease (COVID-19) that started in 2019 has evoked an urgent demand for finding new potential therapeutic agents. In this study, we performed a molecular docking of anti-HIV drugs to refine HIV protease inhibitors and nucleotide analogues to target COVID-19. The evaluation was based on docking scores calculated by AutoDock Vina and top binding poses were analyzed. Our results suggested that lopinavir, darunavir, atazanavir, remdesivir, and tipranavir have the best binding affinity for the 3-chymotrypsin-like protease of COVID-19. The comparison of the binding sites of three drugs, namely, darunavir, atazanavir and remdesivir, showed an overlap region of the protein pocket. Our study showed a strong affinity between lopinavir, darunavir, atazanavir, tipranavir and COVID-19 protease. However, their efficacy should be confirmed by in vitro studies since there are concerns related to interference with their active sites.

References

1. F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, M.-L. Yuan, Y.-L. Zhang, F.-H. Dai, Y. Liu, Q.-M. Wang, J.-J. Zheng, L. Xu, E. C. Holmes and Y.-Z. Zhang, A new coronavirus associated with human respiratory disease in China, Nature 579 (2020) 265–269; https://doi.org/10.1038/s41586-020-2008-310.1038/s41586-020-2008-3709494332015508
Search in Google Scholar Back to article
2. J. Xu, S. Zhao, T. Teng, A. E. Abdalla, W. Zhu, L. Xie, Y. Wang and X. Guo, Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV, Viruses 12 (2020) Article ID 244; https://doi.org/10.3390/v1202024410.3390/v12020244707719132098422
Search in Google Scholar Back to article
3. Z. Wang, X. Chen, Y. Lu, F. Chen and W. Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, Biosci. Trends 14 (2020) 64–68; https://doi.org/10.5582/bst.2020.0103010.5582/bst.2020.0103032037389
Search in Google Scholar Back to article
4. J. Lim, S. Jeon, H. Y. Shin, M. J. Kim, Y. M. Seong, W. J. Lee, K. W. Choe, Y. M. Kang, B. Lee and S. J. Park, Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR, J. Korean Med. Sci. 35 (2020) e79; https://doi.org/10.3346/jkms.2020.35.e7910.3346/jkms.2020.35.e79702591032056407
Search in Google Scholar Back to article
5. C. M. Chu, V. C. Cheng, I. F. Hung, M. M. Wong, K. H. Chan, K. S. Chan, R. Y. Kao, L. L. Poon, C. L. Wong, Y. Guan, J. S. Peiris and K. Y. Yuen, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax 59 (2004) 252–256; https://doi.org/10.1136/thorax.2003.01265810.1136/thorax.2003.012658174698014985565
Search in Google Scholar Back to article
6. S. J. Hurwitz and R. F. Schinazi, Practical considerations for developing nucleoside reverse transcriptase inhibitors, Drug Discov. Today Technol. 9 (2012) e183–e193; https://doi.org/10.1016/j.ddtec.2012.09.00310.1016/j.ddtec.2012.09.003361202523554824
Search in Google Scholar Back to article
7. N. Atatreh, S. Hasan, B. R. Ali and M. A. Ghattas, Computer-aided approaches reveal trihydroxychroman and pyrazolone derivatives as potential inhibitors of SARS-CoV-2 virus main protease, Acta Pharm. 71 (2021) 325–333; https://doi.org/10.2478/acph-2021-004010.2478/acph-2021-0040
Search in Google Scholar Back to article
8. Z. Lv, Y. Chu and Y. Wang, HIV protease inhibitors: a review of molecular selectivity and toxicity, HIV/AIDS (Auckland) 7 (2015) 95–104; https://doi.org/10.2147/HIV.S7995610.2147/HIV.S79956439658225897264
Search in Google Scholar Back to article
9. Y. Wang, J. Xiao, T. O. Suzek, J. Zhang, J. Wang, Z. Zhou, L. Han, K. Karapetyan, S. Dracheva, B. A. Shoemaker, E. Bolton, A. Gindulyte and S. H. Bryant, PubChem’s BioAssay Database, Nucleic Acids Res. 40 (2012) D400-D412; https://doi.org/10.1093/nar/gkr113210.1093/nar/gkr1132324505622140110
Search in Google Scholar Back to article
10. N. M. O’Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch and G. R. Hutchison, Open Babel: An open chemical toolbox, J. Cheminform. 3 (2011) Article ID 33; https://doi.org/10.1186/1758-2946-3-3310.1186/1758-2946-3-33319895021982300
Search in Google Scholar Back to article
11. O. Trott and A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010) 455–461; https://doi.org/10.1002/jcc.2133410.1002/jcc.21334304164119499576
Search in Google Scholar Back to article
12. R. A. Laskowski and M. B. Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, J. Chem. Inf. Model. 51 (2011) 2778–2786; https://doi.org/10.1021/ci200227u10.1021/ci200227u21919503
Search in Google Scholar Back to article
13. M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong and G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. 30 (2020) 269–271; https://doi.org/10.1038/s41422-020-0282-010.1038/s41422-020-0282-0705440832020029
Search in Google Scholar Back to article
14. S. Daoud, S. J. Alabed, L. A. Dahabiyeh, Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies, Acta Pharm. 71 (2021) 163–174; https://doi.org/10.2478/acph-2021-001610.2478/acph-2021-001633151166
Search in Google Scholar Back to article
15. T. P. Sheahan, A. C. Sims, S. R. Leist, A. Schäfer, J. Won, A. J. Brown, S. A. Montgomery, A. Hogg, D. Babusis, M. O. Clarke, J. E. Spahn, L. Bauer, S. Sellers, D. Porter, J. Y. Feng, T. Cihlar, R. Jordan, M. R. Denison and R. S. Baric, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat. Commun. 11 (2020) Article ID 222; https://doi.org/10.1038/s41467-019-13940-610.1038/s41467-019-13940-6695430231924756
Search in Google Scholar Back to article
16. A. H. de Wilde, D. Jochmans, C. C. Posthuma, J. C. Zevenhoven-Dobbe, S. van Nieuwkoop, T. M. Bestebroer, B. G. van den Hoogen, J. Neyts and E. J. Snijder, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob. Agents Chemother. 58 (2014) 4875–4884; https://doi.org/10.1128/AAC.03011-1410.1128/AAC.03011-14413607124841269
Search in Google Scholar Back to article
17. E. C. Vatansever, K. S. Yang, K. Kratch, A. Drelich, C.-C. Cho, D. M. Mellot, S. Xu, C.-T. K. Tseng and W. R. Liu, Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19, bioRxiv preprint [Internet], posted May 23, 2020; https://doi.org/10.1101/2020.05.23.11223510.1101/2020.05.23.112235726349832511370
Search in Google Scholar Back to article
18. B. R. Beck, B. Shin, Y. Choi, S. Park and K. Kang, Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Comput. Struct. Biotechnol. J. 18 (2020) 784–790; https://doi.org/10.1016/j.csbj.2020.03.02510.1016/j.csbj.2020.03.025711854132280433
Search in Google Scholar Back to article
19. M. A. M. Subbaiah, S. Mandlekar, S. Desikan, T. Ramar, L. Subramani, M. Annadurai, S. D. Desai, S. Sinha, S. M. Jenkins and M. R. Krystal, Design, synthesis, and pharmacokinetic evaluation of phosphate and amino acid ester prodrugs for improving the oral bioavailability of the HIV-1 protease inhibitor atazanavir, J. Med. Chem. 62 (2019) 3553–3574; https://doi.org/10.1021/acs.jmedchem.9b0000210.1021/acs.jmedchem.9b0000230938524
Search in Google Scholar Back to article
20. M. Rittweger and K. Arastéh, Clinical pharmacokinetics of darunavir, Clin. Pharmacokin. 46 (2007) 739–756; https://doi.org/10.2165/00003088-200746090-0000210.2165/00003088-200746090-0000217713972
Search in Google Scholar Back to article
21. M. Mahdi, J. A. Mótyán, Z. I. Szojka, M. Golda, M. Miczi and J. Tőzsér, Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2’s main protease, Virol. J. 17 (2020) Article ID 190; https://doi.org/10.1186/s12985-020-01457-010.1186/s12985-020-01457-0768964033243253
Search in Google Scholar Back to article
22. S. Jo, S. Kim and D. H. Shin, Inhibition of SARS-CoV 3CL protease by flavonoids, J. Enzyme Inhib. Med. Chem. 35 (2020) 145–151; https://doi.org/10.1080/14756366.2019.169048010.1080/14756366.2019.1690480688243431724441
Search in Google Scholar Back to article
23. L. Zhang, D. Lin, Y. Kusov, Y. Nian, Q. Ma, J. Wang, A. von Brunn, P. Leyssen, K. Lanko, J. Neyts, A. de Wilde, E. J. Snijder and H. Liu, α-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment, J. Med. Chem. 63 (2020) 4562–4578; https://doi.org/10.1021/acs.jmedchem.9b0182810.1021/acs.jmedchem.9b01828709807032045235
Search in Google Scholar Back to article
24. M. M. Ghahremanpour, J. Tirado-Rives, M. Deshmukh, J. A. Ippolito, C.-H. Zhang, I. Cabeza de Vaca, M.-E. Liosi, K. S. Anderson and W. L. Jorgensen, Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2, ACS Med. Chem. Lett. 11 (2020) 2526–2533; https://doi.org/10.1021/acsmedchemlett.0c0052110.1021/acsmedchemlett.0c00521760532833324471
Search in Google Scholar Back to article

Evaluation of COVID-19 protease and HIV inhibitors interactions

Abstract

Paradigm

My account